GOSS News and Press, Gossamer Bio Inc. From 02/18/20

Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Seth Klarman’s Baupost Group Holdings ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple as...

10x Genomics (NASDAQ: TXG ) initiated with Buy rating and $100 (32% upside) price target at Citigroup. More news on: 10x Genomics, Inc., AbbVie Inc., AdaptHealth Corp., Healthcare stocks news, Stocks on the move, , Read more ...

Gainers: Mirum Pharmaceuticals (NASDAQ: MIRM )  +110% . More news on: Mirum Pharmaceuticals, Inc., Axsome Therapeutics, Inc., The Goldfield Corporation, Stocks on the move, Read more ...

Wave Life Sciences WVE  -52% . More news on: Gossamer Bio, Inc., PG&E Corporation, NantKwest, Inc., , Stocks on the move Read more ...

Novartis (NYSE: NVS ) has decided to stop development of fevipiprant after a series of unsuccessful clinical trials. In October, the DP2 antagonist failed improve lung function in two Phase 3 studies in patients with moderate asthma. More news on: Novartis AG, Gossamer Bio, Inc., Healthc...

Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BeyondSpring (NASDAQ: BYSI ) initiated with Market Perform rating at Oppenheimer. More news on: BeyondSpring Inc., Centogene N.V., Curaleaf Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...